Skip to main content

Table 1 Patient characteristics at baseline (ITT population)

From: Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency

 

Prolastin

(n = 38)

Placebo

(n = 39)

p value

Age (years, mean ± SD)

54.7 ± 8.4

55.3 ± 9.8

0.749

Gender (n, male/female)

25/13

16/23

0.021

FEV1% predicted (mean ± SD)

46.3 ± 19.6

46.6 ± 21.0

0.873

PD15 (g/L, mean ± SD)a

   

Whole lung

47.98 ± 19.07

45.48 ± 16.95

0.288

Apical region

63.36 ± 24.96

62.96 ± 19.77

0.625

Middle region

51.48 ± 18.35

48.35 ± 18.40

0.232

Basal region

38.61 ± 18.90

34.94 ± 15.44

0.182

MLD (g/L, mean ± SD)a

131.57 ± 21.99

131.68 ± 18.89

0.719

VI-910 (%, mean ± SD)a

44.43 ± 13.66

45.11 ± 12.02

0.509

VI-950 (%, mean ± SD)a

18.66 ± 10.97

19.77 ± 9.81

0.435

Lung weight (g, mean ± SD)a

956.40 ± 140.64

946.09 ± 224.12

0.750

Lung volume (L, mean ± SD)a

7.46 ± 1.60

7.27 ± 1.78

0.557

  1. SD, standard deviation; FEV1, forced expiratory volume in 1 second; PD15, 15th percentile lung density; MLD, mean lung density; VI-910, voxel index at a threshold of -910 (measured in %); VI-950, voxel index at a threshold of -950 (measured in %). aFor the CT densitometric analyses, the mITT population was used (n = 36, Prolastin; n = 35, placebo).
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us